These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21233678)

  • 1. Clinicopathological features of hepatitis C virus disease after living donor liver transplantation: relationship with in situ hybridisation data.
    Masuda Y; Nakazawa Y; Matsuda K; Sano K; Mita A; Ohno Y; Urata K; Ikegami T; Miwa S; Miyagawa S
    Pathology; 2011 Feb; 43(2):156-60. PubMed ID: 21233678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
    Ueda Y; Takada Y; Marusawa H; Egawa H; Uemoto S; Chiba T
    Transplantation; 2010 Sep; 90(6):661-5. PubMed ID: 20110853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation.
    Yedibela S; Schuppan D; Müller V; Schellerer V; Tannapfel A; Hohenberger W; Meyer T
    Liver Int; 2005 Aug; 25(4):717-22. PubMed ID: 15998420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease.
    Eurich D; Neumann UP; Boas-Knoop S; Neuhaus R; Kiessling A; Yahyazadeh A; Trautwein C; Wasmuth H; Puhl G; Neuhaus P; Bahra M
    J Gastroenterol Hepatol; 2013 Jan; 28(1):153-60. PubMed ID: 22989351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
    Rodriguez-Luna H; Khatib A; Sharma P; De Petris G; Williams JW; Ortiz J; Hansen K; Mulligan D; Moss A; Douglas DD; Balan V; Rakela J; Vargas HE
    Transplantation; 2004 Jan; 77(2):190-4. PubMed ID: 14742979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
    Park JI; Choi KM; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Chung YH; Lee YS; Suh DJ
    Korean J Hepatol; 2007 Dec; 13(4):543-55. PubMed ID: 18159152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
    Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient.
    Montalbano M; Pasulo L; Sonzogni A; Remuzzi G; Colledan M; Strazzabosco M
    J Clin Gastroenterol; 2007 Feb; 41(2):216-20. PubMed ID: 17245223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S
    Transplant Proc; 2005 Dec; 37(10):4403-5. PubMed ID: 16387131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
    Neff GW; O'Brien CB; Cirocco R; Montalbano M; de Medina M; Ruiz P; Khaled AS; Bejarano PA; Safdar K; Hill MA; Tzakis AG; Schiff ER
    Liver Transpl; 2004 May; 10(5):595-8. PubMed ID: 15108250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymoglobulin for steroid-resistant immune-mediated graft dysfunction during simeprevir-based antiviral treatment for post-transplantation hepatitis C: case report.
    Takeishi K; Ikegami T; Yoshizumi T; Itoh S; Harimoto N; Harada N; Tsujita E; Kimura Y; Yamashita Y; Saeki K; Oki E; Shirabe K; Maehara Y
    Transplant Proc; 2015 Apr; 47(3):794-5. PubMed ID: 25891734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection.
    Iwai A; Marusawa H; Takada Y; Egawa H; Ikeda K; Nabeshima M; Uemoto S; Chiba T
    J Viral Hepat; 2006 Aug; 13(8):523-31. PubMed ID: 16901282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin.
    Neumann U; Puhl G; Bahra M; Berg T; Langrehr JM; Neuhaus R; Neuhaus P
    Transplantation; 2006 Jul; 82(1):43-7. PubMed ID: 16861940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection.
    Coppola N; Pisapia R; Tonziello G; Martini S; Imparato M; Piai G; Stanzione M; Sagnelli C; Filippini P; Piccinino F; Sagnelli E
    Antivir Ther; 2008; 13(2):307-18. PubMed ID: 18505182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.